BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wierzbowska A, Urbańska-Ryś H, Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999;105:412-9. [PMID: 10233412 [PMID: 10233412 DOI: 10.1111/j.1365-2141.1999.01350.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Aki SZ, Sucak GT, Paşaoğlu H, Ozkurt ZN, Yegin ZA, Ofluoğlu E, Yağci M, Haznedar R. Thrombopoietic cytokine and P-selectin levels in patients with multiple myeloma undergoing autologous stem cell transplantation: decrease in posttransplantation P-selectin levels might predict the degree of maximum response. Clin Lymphoma Myeloma 2009;9:229-33. [PMID: 19525192 DOI: 10.3816/CLM.2009.n.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dörken B, Bargou RC. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-90. [PMID: 15356648 DOI: 10.1038/sj.leu.2403486] [Cited by in Crossref: 84] [Cited by in F6Publishing: 69] [Article Influence: 4.9] [Reference Citation Analysis]
3 Nguyen MLT, Bui KC, Scholta T, Xing J, Bhuria V, Sipos B, Wilkens L, Nguyen Linh T, Velavan TP, Bozko P, Plentz RR. Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma. J Gastroenterol Hepatol 2021;36:1334-45. [PMID: 33091158 DOI: 10.1111/jgh.15307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kimata H. Ciliary neurotrophic factor preferentially enhances spontaneous IgE production by B cells from atopic patients. Neuropeptides 2004;38:92-7. [PMID: 15223271 DOI: 10.1016/j.npep.2004.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
5 Kovacs E, Kuehn J. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does Viscum album treatment affect these parameters? Biomedicine & Pharmacotherapy 2002;56:152-8. [DOI: 10.1016/s0753-3322(02)00165-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ohtani T, Ishihara K, Atsumi T, Yoshida Y, Nishida K, Narimatsu M, Shirogane T, Hibi M, Hirano T. gp130-mediated signalling as a therapeutic target. Emerging Therapeutic Targets 2005;4:459-79. [DOI: 10.1517/14728222.4.4.459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
7 Obreja O, Schmelz M, Poole S, Kress M. Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain 2002;96:57-62. [DOI: 10.1016/s0304-3959(01)00420-1] [Cited by in Crossref: 82] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
8 Lambotte O, Royer B, Genet P, Brice P, Brouet J, Fermand J. Multiple myeloma presenting as fever of unknown origin. European Journal of Internal Medicine 2003;14:94-7. [DOI: 10.1016/s0953-6205(03)00021-9] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
9 Zheng C, Huang D, Bergenbrant S, Sundblad A, Österborg A, Björkholm M, Holm G, Yi Q. Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma: Cytokine Polymorphism in Multiple Myeloma. British Journal of Haematology 2000;109:39-45. [DOI: 10.1046/j.1365-2141.2000.01963.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
10 Koskela K, Pelliniemi T, Pulkki K, Remes K. Treatment of Multiple Myeloma with All-Trans Retinoic Acid Alone and in Combination with Chemotherapy: a Phase I/II Trial. Leukemia & Lymphoma 2009;45:749-54. [DOI: 10.1080/10428190310001628158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
11 Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:46-52. [PMID: 12095927 DOI: 10.1111/j.1749-6632.2002.tb04093.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
12 Obreja O, Biasio W, Andratsch M, Lips KS, Rathee PK, Ludwig A, Rose-john S, Kress M. Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain 2005;128:1634-41. [DOI: 10.1093/brain/awh490] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 4.9] [Reference Citation Analysis]
13 Kelleher JH, Tewari D, McMahon SB. Neurotrophic factors and their inhibitors in chronic pain treatment. Neurobiol Dis 2017;97:127-38. [PMID: 27063668 DOI: 10.1016/j.nbd.2016.03.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
14 Vergara C, Ramirez B. CNTF, a pleiotropic cytokine: emphasis on its myotrophic role. Brain Research Reviews 2004;47:161-73. [DOI: 10.1016/j.brainresrev.2004.07.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
15 Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem. 2001;276:39508-39511. [PMID: 11551897 DOI: 10.1074/jbc.C100343200] [Cited by in Crossref: 113] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
16 Rawstron AC, Fenton JAL, Ashcroft J, English A, Jones RA, Richards SJ, Pratt G, Owen R, Davies FE, Child JA, Jack AS, Morgan G. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000;96:3880-6. [DOI: 10.1182/blood.v96.12.3880.h8003880_3880_3886] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
17 Rawstron AC, Fenton JAL, Ashcroft J, English A, Jones RA, Richards SJ, Pratt G, Owen R, Davies FE, Child JA, Jack AS, Morgan G. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000;96:3880-6. [DOI: 10.1182/blood.v96.12.3880] [Cited by in Crossref: 55] [Article Influence: 2.6] [Reference Citation Analysis]
18 Allegra A, Penna G, Alonci A, Russo S, Greve B, Innao V, Minardi V, Musolino C. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013;90:441-68. [DOI: 10.1111/ejh.12107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
19 Won HS, Kim YA, Lee JS, Jeon EK, An HJ, Sun DS, Ko YH, Kim JS. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer. Cancer Invest 2013;31:516-21. [PMID: 23902164 DOI: 10.3109/07357907.2013.826239] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
20 Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou N. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7. [DOI: 10.1016/s8756-3282(02)00915-8] [Cited by in Crossref: 312] [Cited by in F6Publishing: 125] [Article Influence: 17.3] [Reference Citation Analysis]
21 Kovacs E. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2? Biomedicine & Pharmacotherapy 2003;57:489-94. [DOI: 10.1016/j.biopha.2003.08.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]